Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects
The company progresses with its Phase 3 ovarian cancer trial while AVMAPKI FAKZYNJA CO-PACK generates revenue.
A doctor consulting a patient about the efficacy of the biopharmaceutical company's drugs.
Verastem, Inc. (NASDAQ:VSTM), operating from its headquarters in Massachusetts, is a development-stage biopharmaceutical company. Its focus is on discovering and commercializing novel cancer therapies, particularly those targeting cancer stem cells and RAS pathway–based malignancies.
On August 8, 2025, Verastem, Inc. (NASDAQ:VSTM) announced an update Phase 3 study in ovarian cancer. The company is engaged in a Phase 3 clinical trial, RAMP 301, to test a new combination therapy for recurrent low-grade serous ovarian cancer (LGSOC).
It announced that the study will focus on assessing the safety and effectiveness of the oral drugs avutometinib and defactinib against standard treatments. It's an open-label, randomized trial, and participants can switch to the new drugs if their disease progresses. The study, which began in March 2024, is crucial for exploring new treatment options for this challenging cancer. It has the potential to impact on the competitive environment in oncology.
Additionally, in its earnings call, Verastem, Inc. (NASDAQ:VSTM) also highlighted securing FDA approval for its AVMAPKI FAKZYNJA CO-PACK nearly two months ahead of schedule. With this approval, the company enters the first-ever treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). The product helped generate $2.1 million in net product revenue within just six weeks of its launch.
The company has a short float of 37.03%, suggesting elevated bearish bets that position the stock for significant gains if a bullish trigger were to materialize.
While we acknowledge the potential of VSTM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon
Disclosure. None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
27 minutes ago
- Forbes
Forget Pickleball. Padel Is The Hot New Court Sport At Luxury Resorts
Tucked away within the 45-acre grounds of the Mediterranean-inspired property, the Padel courts at Rancho Valencia in San Diego are part of a partnership with Spain-based company Grupo Padel Galis World and the sports company Wilson. Rancho Valencia Maybe all that pickleball 'dinking' finally got on people's nerves. Or perhaps resort guests just wanted something a bit more refined than a sport you can play at the local rec center. Either way — and the fact that it's energizing and kinda glamorous certainly doesn't hurt — padel has suddenly become a hot new court sport at U.S. luxury resorts. Padel is a racket sport played on an enclosed turf or carpet surface roughly the size of a doubles tennis court, combining elements of pickleball, tennis and paddle tennis. The key twist: the walls are in play, like in squash, which adds a whole extra dimension of strategy and engagement. Rancho Valencia installed three new padel courts this past winter as part of an expanded racket sports program that includes coaching, equipment and various clinics and tournaments. Rancho Valencia Though it originated in 1960s Mexico, padel is massively popular in countries such as Spain and Argentina and it's spreading fast. According to the 2025 Global Padel Report from Playtomic and PwC, over 7,000 new padel courts opened worldwide in 2024 along with more than 3,200 new padel clubs, driven by growth in France, the U.K., Germany and the U.S. With all the interest, more than 81,000 padel courts are expected to be built by 2027. Padel rackets are similar to the paddles used in paddle tennis and platform tennis. These Wilson Bela pro paddles were seen off the court during the Italy Major Premier Padel in 2022. (Photo by Andrea Staccioli/Insidefoto/LightRocket via Getty Images) Insidefoto/LightRocket via Getty Images Now the U.S. hotel market is catching on. From The Ritz-Carlton in Key Biscayne and Boar's Head Resort in Charlottesville, Virginia, to The Houstonian Hotel, Club & Spa in Houston, Texas, the sport is becoming a baseline experience. If a self-respecting tennis and pickleball resort doesn't have a padel court already, it probably will soon. "We couldn't be more excited to take our offerings to the next level with the unveiling of new Padel courts,' says Rancho Valencia General Manager Milan Drager. Rancho Valencia In California, Rancho Valencia, which already had a robust racket sports program, is setting new standards for padel. After teaming up with Wilson and Valencia, Spain-based design firm Grupo Padel Galis World, the San Diego resort this year built out a full padel program, complete with three courts, equipment, coaching support and a slate of weekly clinics and drop-ins. Guests can book a court like they would a spa appointment and everything is waiting when you show up. They're also planning multi-day events, advanced clinics and monthly 'Americano tourney' play. And the resort definitely didn't skimp on coaching talent. François Catejón — a former No. 1–ranked U.S. padel player in the 35+ division — now teaches at Rancho Valencia and helps run the on-court programming. For those who like to follow a forehand winner with something shaken over ice, Rancho Valencia now offers a courtside cocktails menu featuring drinks like the Berry Deuce, Bourbon Cherry Smash, Bandeja and Up A Creek. It's all made for post-padel sips — and, who knows, maybe for making peace with those pickleball friends who haven't quite made the switch to padel just yet. ALSO ON FORBES Forbes Why Beverly Hills' Power Players Might Lose A Beloved Dining Spot By David Hochman Forbes Smart Ovens Breville, June And Chef IQ Battle For Your Countertop By David Hochman Forbes No Script, No Problem. The Improvised Shakespeare Company Turns 20 By David Hochman
Yahoo
32 minutes ago
- Yahoo
Nick Pivetta breaks silence on $55 million Padres decision
Nick Pivetta breaks silence on $55 million Padres decision originally appeared on The Sporting News The San Diego Padres didn't make a ton of moves in the offseason, as they instead bolstered the roster at the trade deadline with a plethora of trades. But one of the moves they did make has worked wonders. In the offseason, the Padres signed veteran starting pitcher Nick Pivetta to a four-year, $55 million contract, with a $14 million opt-out in 2027 and an $18 million player option in 2028. Kevin Acee of The San Diego Union-Tribune shared the reason why Pivetta decided to sign with the Padres and leave the $21 million deal on the table from the Boston Red Sox. "It's a lot of money," Pivetta said. "So I think anytime you get offered $21 million to play for one year, it's life-changing money for the year. But it's not about the one year. It's been multiple years." The $21 million for one year Pivetta is referring to comes from the Red Sox, the team he pitched for in 2024, offering him a $21.05 million qualifying offer. Turning down so much money, especially for Pivetta, who hasn't inked such a deal, was a tough decision. "It's about where I am going to be in five years," Pivetta said, "where I am going to be in six years, how I am going to set myself up for success in those years, and continue to make money, which I will, and it's going to be fine." MORE: Padres' Michael King gets encouraging contract extension update Pivetta, instead of capitalizing on a one-year deal worth $21 million, decided to look towards the future to better set himself up for success. That doesn't mean he skimped on his current deal. "I'm still making stupid amounts of money," Pivetta admitted. "But I'm always willing to bet on myself. I like to gamble, I like to have fun, and I believe in myself a lot." The 32-year-old right-hander has been amazing for San Diego this season. In 24 starts, Pivetta has a 2.87 ERA, a 12-4 record, a career-high 4.2 WAR, 144 strikeouts, and a 149 ERA+ across 141.1 innings pitched. With the injuries to Yu Darvish for the first half and Michael King for a few months, along with the struggles of Dylan Cease at times this year, Pivetta has been integral to the Padres' success. His decision to turn down the $21 million deal from the Red Sox to sign with the Padres for the 2025 and 2026 seasons at least has been an incredible development for the Padres. He's been exactly what they need, and would easily be worth $21 million this year based on his production on the mound. MORE MLB NEWS: Padres' Mason Miller breaks silence on potential switch to starting rotation Cardinals' pair of left-handed-hitting outfielders could be dealt in offseason Astros' Carlos Correa reveals Gold Glove influence amid third base transition Cardinals' Oli Marmol provides bleak Nolan Arenado injury update Guardians' veteran right-handed pitcher sold to KBO Lotte Giants Tigers top prospects could be impacted by $130 million Roman Anthony Red Sox contract
Yahoo
34 minutes ago
- Yahoo
What To Expect From Workday's (WDAY) Q2 Earnings
Enterprise software company Workday (NASDAQ:WDAY) will be reporting results this Thursday after market hours. Here's what investors should know. Workday beat analysts' revenue expectations by 1% last quarter, reporting revenues of $2.24 billion, up 12.6% year on year. It was a satisfactory quarter for the company, with a solid beat of analysts' EBITDA estimates but a significant miss of analysts' billings estimates. Is Workday a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Workday's revenue to grow 12.3% year on year to $2.34 billion, slowing from the 16.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.11 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Workday has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 0.9% on average. Looking at Workday's peers in the finance and hr software segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Marqeta delivered year-on-year revenue growth of 20.1%, beating analysts' expectations by 6.9%, and Workiva reported revenues up 21.2%, topping estimates by 3%. Marqeta traded up 19.9% following the results while Workiva was also up 32.2%. Read our full analysis of Marqeta's results here and Workiva's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the finance and hr software stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.6% on average over the last month. Workday is down 1.5% during the same time and is heading into earnings with an average analyst price target of $293.69 (compared to the current share price of $230.17). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
